Following approval by CRG, GMMMG, and the Greater Manchester ICS Clinical Effectiveness and Governance Committee, the following decisions have been approved and published:

  • Insuman Comb 50 removed from formulary – product discontinued
  • Abrocitinib, tralokinumab & upadacitinib added for formulary as RED drugs in chapter 13

The formulary has also been updated to reflect relevant NICE guidelines and safety alerts. For full details please see the formulary change log, which is available on the formulary page.

For more information on these and other decisions, please see GMMMG decision summaries.